Gaurav Shah, Rocket Pharmaceuticals CEO
Renovacor ships its cardiac gene therapy to Rocket in $53M all-stock deal
Renovacor wanted to be in the clinic already. The biotech expected an $11 million Series A in summer 2019 would bankroll an IND filing for …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
